Likewise, 40% (27 of 68) invasive ductal carcinoma, 68% (15 of 22) invasive lobular carcinoma and more than 94% (30 of 32) metastases were completely negative for PRRX1 (Fig. 7f), whereas 90% (27 of 30) ductal/lobular carcinoma in situ and fibroadenoma were positive. Here, PRRX1 is linked to invasive ductal breast carcinoma.